Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 15

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 15
---
 financial statements and related notes included elsewhere in this prospectus, before making an investment decision. Overview We are an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Our proprietary approach to T cell engineering, which enables us to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Our novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in pathways that employ both cytotoxic and phagocytic mechanisms to destroy cancer cells, creating what we refer to as Chimeric Engulfment Receptor T (“CER-T”) cells. Our lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. Unlike currently approved chimeric antigen receptor (“CAR-T”) therapies which have largely been active in hematological B cell malignancies, we believe CER-1236 will be efficacious in both hematological malignancies and solid tumors. Recent Developments Keystone Equity Financing In February 2024, we entered into a common stock purchase agreement (the “Old Keystone Purchase Agreement”) with Keystone, pursuant to which we may sell and issue, and Keystone is obligated to purchase, up to $25,000,000 of shares of Common Stock (the “Keystone Purchase Shares”); provided that the number of shares issued pursuant to the Old Keystone Purchase Agreement shall not exceed 250,000 shares (the “Initial Limit”). As consideration for Keystone’s commitment to purchase shares of Common Stock pursuant to the Keystone Purchase Agreements, we issued an aggregate of 19,833 shares of Common Stock to Keystone (the “Keystone Commitment Shares”). We previously filed a registration statement on Form S-1 (File No. 333-278603), which was declared effective by the SEC on May 1, 2024, and remains in effect (the “Prior Registration Statement”), with respect to up to (i) 250,000 Keystone Purchase Shares and (ii) 6,191 Keystone Commitment Shares. In November 2024, in order to enable us to issue and sell additional shares in excess of the Initial Limit and up to $25,000,000, we entered into the New Keystone Purchase Agreement with Keystone, pursuant to which we may issue and sell up to $20,589,384 of shares of Common Stock. Through January 8,